UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner
`
`V.
`
`WARNER CHILCOTT COMPANY, LLC.,
`
`Patent Owner
`
`Case IPR2015—00682
`
`Patent 7,704,984
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`
`DC: 580676]-1
`
`

`
`IPR2015—00682
`
`List of Exhibits
`
`2002
`
`2003
`
`2004
`
`2005
`
`
` opinion fromwatnerchizcott C0,, LLC v. L..,..—..Ltd. et at, C
`2001
`Civ. A. Nos. 11-05048, 12-2928 D.N.J. Jan. 17, 2014
`Opinion from Warner Chilcott Co., LLC v. Lupin Ltd., et al,
`Nos. 2014-1267, -1273 Fed. Cir. Oct. 22, 2014
`Excerpts of Trial Transcripts from Warner Chilcott Co., LLC v.
`Lupin Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 (D.N.J. Oct.
`7-17, 2013
`Speroff, L. & P.D. Darney, A Clinical Guide for Contraception
`(4th ed. 2005) (PTX 83 from Warner Chilcott Co., LLC v. Lupin
`Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Speroff, L. & Darney, P.D., A Clinical Guide for Contraception
`(3d ed. 2001) (PTX 82A from Warner Chilcott Co., LLC v.
`Lu in Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 (D.N.J.!)
`Prescribin Information for L0 Loestrin Fe
`van Heusden, A.M., Fauser, B.C.J.M., “Activity of the pituitary-
`ovarian axis in the pill-free interval during use of low-dose
`combined oral contraceptives,” Contraception, 1999; 59:237-
`243. (DTX 507 from Warner Chilcott Co., LLC v. Lupin Ltd. et
`al., Civ. A. Nos. 11-05048, 12-2928
`Teichmann, A.T., et al., “The influence of the dose of ethinyl
`estradiol in oral contraceptives on follicle growth,” Gynecol.
`Endocrinol. 1995; 9:299-305. (DTX 477 Warner Chilcott Co.,
`LLC v. Lupin Ltd. et al., Civ. A. Nos. 11-05048, 12-2928
`D.N.J.
`
`2006
`
`2007
`
`2008
`
`2009
`
`L 2010
`
`U.S. Patent 5,980,940 (JTX 16 from Warner Chilcott Co., LLC
`v. Lupin Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 tD.N.J.))
`Kaunitz, A., Oral Contraceptive Estrogen Dose Considerations,
`58 Contraception 15S (1998) (PTX 48 from Warner Chilcott
`Co., LLC v. Lupin Ltd. et al., Civ. A. Nos. 11-05048, 12-2928
`D.N.J.
`
`2011
`
`2012
`
`Darney, P., OC Practice Guidelines: Minimizing Side Effects,
`42 Int’l J. Fertility & Women’s Med. 158 (Suppl. 1 1997) (PTX
`21 from Warner Chilcott Co., LLC v. Lupin Ltd. et al., Civ. A.
`Nos. 11-05048, 12-2928 D.N.J.
`Thorneycroft, I. & Cariati, S., Ultra-Low-Dose Oral
`Contrace tives: Are The Riht for Your Patient?,
`
`1
`
`

`
`
`
`
`
`
`
`
`
`IPR2015—00682
`
`
`
`
`
`2013
`
`
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`2021
`
`
`
`
`
`
`
`1y 3, 2001 (PTX 99 from Warner
`wvvw.medscape.com, Ju
`Chilcott Co., LLC v. Lupin Ltd. et al., Civ. A. Nos. 11-05048,
`
`
`12-2928
`.
`.
`.
`Akerlund et al., Comparative Profiles of Reliability, Cycle
`Control and Side Effects of Two Oral Contraceptive
`
`Formulations Containing 150 mcg Desogestrel and Either 30 or
`20 mcg Ethinyl Estradiol, 100 Brit. J. Obstet. Gynecol. 832
`(1993) (PTX 1 from Warner Chilcott Co., LLC v. Lupin Ltd. et
`al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.))
`Marut, E., Oral Contraceptives; Who, Which, When, and Why,
`82 Postraduate Medicine, 1987
`U.S. Patent No. 4,292,315 (PTX 112 Warner Chilcott Co., LLC
`v. Lu in Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Serfaty, D., The 20 Microgram Ethinyl Estradiol Plus 150
`Microgram Desogestrel Pill Multicenter Study on 235 Women
`for 6 Months, 18 Contraception—fertilite sexualite 407 (1990)
`(PTX 78) from Warner Chilcott Co., LLC v. Lupin Ltd. et al.,
`Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Lammers et al., Double-blind comparative acceptability study
`with two combined oral contraceptives containing 20 ug
`ethinylestradiol plus desogestrel or norethisterone acetate, in
`Optimizing the estrogen dose in oral contraceptives 67-74
`(1992) (PTX 52 from Warner Chilcott Co., LLC v. Lupin Ltd. et
`al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Task Force on Oral Contraceptives, A randomized, double—blind
`study of six combined oral contraceptives, 25 Contraception 231
`(Mar. 1982) (PTX 97 from Warner Chilcott Co., LLC v. Lupin
`Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Bounds, et al., A Randomized Double-Blind Trial of Two Low
`Dose Combined Oral Contraceptives, 86 Brit. J . Obstetrics 325
`(1979) (PTX 10 from Warner Chilcott Co., LLC v. Lupin Ltd. et
`al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Szarewski, A. & Guillebaud, J ., Contraception: A User’s
`Handbook (1998) (PTX 93 from Warner Chilcott Co., LLC v.
`
`Lain Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`U.S. Patent 4,921,843 (JTX 15 from Warner Chilcott Co., LLC
`v. Lain Ltd. et al., Civ. A. Nos. 11-05048, 12-2928
`
`
`
`2022
`
`Exce ts from the Deosition Transcri t of Kurt Bamhart, M.D.
`
`2
`
`

`
`IPR2015—00682
`
`Miscellaneous Exhibits introduced at trial by Lupin Ltd. and
`Amneal Pharmaceuticals in Warner Chilcott Co., LLC v. Lupin
`
`Sullivan et al., Effect of 21-day and 24-day oral contraceptive
`regimens containing gestodene (60 lag) and ethinyl estradiol (15
`ug) on ovarian activity, 72 Fertility & Sterility 115 (July 1999)
`(PTX 91 from Warner Chilcott Co., LLC v. Lupin Ltd. et al.,
`
`Gestodene Study Group 324, Cycle control, safety and efficacy
`of a 24-day regimen of gestodene 60 ug/ethinylestradiol 15 ug
`and a 21- day regimen of desogestrel 150 ug/ethinylestradiol 20
`pg, 4 Eur. J. Contraception & Reproductive Health Care 17
`(Suppl. 2 1999) (PTX 37 from Warner Chilcott C0,, LLC v.
`Lain Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Endrikat, J ., et al., “Double-blind, multicenter comparison of
`efficacy, cycle control, and tolerability of a 23-day versus a 21-
`day low-dose oral contraceptive regimen containing 20 mcg
`ethinyl estradiol and 75 meg gestodene,” Contraception, 2001;
`64:99-105. (DTX 520 from Warner Chilcott Co., LLC v. Lupin
`Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Szarewski, A. & Guillebaud, J., Contraception: A User’s Guide
`(3d ed. 2004) (PTX 92 from Warner Chilcott Co., LLC v. Lupin
`Ltd. et al., Civ. A. Nos. 11-05048, 12-2928 D.N.J.
`Complaint of Warner Chilcott Co., LLC. in Warner Chilcott Co.
`LLC v. M lan, Inc. et al., Civ. No. 3:13-06560 D.N.J.
`Answer and Counterclaims of Mylan in Warner Chilcott Co.
`LLC v. M lan, Inc. et al., Civ. No. 3:13-06560 D.N.J.
`Scheduling Order in Warner Chilcott Co. LLC v. Mylan, Inc. et
`al., Civ. No. 3:13-06560 D.N.J.
`Thomas MA. Contraception. Conn’s Current Therapy, pp.
`1123-8, 2001.
`Thomas MA: Fertility Control and Contraception. Gynecology
`& Obstetrics, A Longitudinal Approach. Chapter III:185-207,
`1993.
`
`2031
`
`2032
`
`2033
`
`Settlement Areement Business Confidential Information)
`
`

`
`IPR2015-00682
`
`Date: August 19, 2015
`
`Respectfully submitted,
`
`ffwmx
`E
`3
`.'
`jg}
`f
`j
`“‘
`By ‘kw,///Z033?,»
`
`Andrea G. Reister, Bag. No. 36,253
`Enrique D. Longton, Reg. No. 47,304
`COVINGTON & BURLING LLP
`
`
`
`
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`

`
`IPR2015—00682
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 19th day of August 2015,
`
`the foregoing Patent Owner’s Updated Exhibit List was served Via email by
`
`agreement of the parties on the following counsel of record for petitioner:
`
`Cedric C.Y. Tan (ctan@mcguirewoods.com)
`McGuireWoods LLP
`
`2001 K Street NW, Suite 400
`Washington, DC 20006—1040
`
`Karen L. Carroll (kcarroll@mcguirewoods.com)
`Brie L.B. Buchanan (bbuchanan@mcguirewoods.com)
`McGuireWoods LLP
`
`1230 Peachtree Street, Suite 2100
`
`Atlanta, Georgia 30309
`
`Dated: August 19, 2015
`
`Reg. No. 36,2’ 3